Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health Study

Modern Pathology

Volumn 24, Issue 7, 2011, Pages 924-931

  Collins, Laura C ^a   Cole, Kimberly S ^a   Marotti, Jonathan D ^b   Hu, Rong ^c,d   Schnitt, Stuart J ^a   Tamimi, Rulla M ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

androgen receptor; breast cancer; molecular subtype

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 79959998479     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.54     Document Type: Article

References (42)

1. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-9217. (Pubitemid 29374734)
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423. (Pubitemid 36842560)
4. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-7360. (Pubitemid 46202348)
5. Millar EK, Graham PH, O0Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009;27:4701-4708.
6. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27: 1168-1176.
7. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-1568. (Pubitemid 39331875)
8. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008;8:149.
9. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170:31-35. (Pubitemid 23130581)
10. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, et al. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer 1992;52:581-584.
11. Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptornegative tumors with apocrine differentiation. Mod Pathol 2010;23:205-212.
12. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003;98:703-711. (Pubitemid 36959265)
13. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008;13:431-435.
14. Baglietto L, Severi G, English DR, et al. Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:492-502.
15. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005; 97:755-765. (Pubitemid 40879595)
16. Lillie EO, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003;5:164-173. (Pubitemid 36519412)
17. Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009;18:169-176.
18. Missmer SA, Eliassen AH, Barbieri RL, et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-1865. (Pubitemid 40081323)
19. Hardin C, Pommier R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg 2007;31:1041-1046. (Pubitemid 46716787)
20. Toth-Fejel S, Cheek J, Calhoun K, et al. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch Surg 2004;139:50-54. (Pubitemid 38049619)
21. Macedo LF, Guo Z, Tilghman SL, et al. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006;66:7775-7782. (Pubitemid 44289238)
22. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32. (Pubitemid 46120191)
23. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671. (Pubitemid 41032603)
24. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
25. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374. (Pubitemid 39100473)
26. Abd El-Rehim DM, Ball G, Pinder SE, et al. Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-350. (Pubitemid 40993329)
27. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671. (Pubitemid 38714103)
28. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996. (Pubitemid 35434844)
29. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24:152-182. (Pubitemid 36515283)
30. Castellano I, Allia E, Accortanzo V, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010;124:607-617.
31. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-731. (Pubitemid 37339680)
32. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616. (Pubitemid 34498648)
33. Wysowski DK, Comstock GW, Helsing KJ, et al. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125: 791-799. (Pubitemid 17066478)
34. Hanley K,Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of highgrade ductal carcinoma of the breast. Hum Pathol 2008;39:386-392.
35. Meijnen P, Peterse JL, Antonini N, et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008;98:137-142.
36. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010;16:62-65.
37. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008;10:542-548. (Pubitemid 351770298)
38. Garreau JR, Muller P, Pommier R, et al. Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptornegative breast cancer cells renders them responsive to hormonal manipulation. Am J Surg 2006;191: 576-580. (Pubitemid 44389521)
39. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-5232.
40. Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-1691.
41. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7: e1000279.
42. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101: 736-750.